CAMBRIDGE, Mass., May 13, 2021– KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer.
“Chris is an seasoned biotech finance executive who brings deep experience in the areas of corporate finance and operations with growing biopharma companies like KSQ,” said Qasim Rizvi, Chief Executive Officer of KSQ Therapeutics. “We are thrilled to have him join our team at this pivotal time in KSQ’s growth trajectory. Our CRISPRomics platform has expansive potential across therapeutic areas and modalities. As we continue to expand and progress our pipeline, his experience will be invaluable.”
“It is an exciting time to be joining KSQ,” said Mr. Heberlig. “The company has shown its platform can discover and deliver on novel targets, and their recent progress and business development success is only the beginning. I look forward to working with this dedicated team as they continue to develop next-generation cell therapies and novel therapeutics for both cancer and autoimmune disease.”
Mr. Heberlig comes to KSQ with over 20 years of experience managing and leading teams, including overseeing the financial and operational responsibilities of private and publicly traded biotechnology companies. Before his new role at KSQ, Chris served as Chief Financial Officer of Kiniksa Pharmaceuticals, where he was part of the company’s founding team and in-licensed a portfolio of products. During his time at Kiniksa, he oversaw three private financing rounds, an initial public offering, and a follow-on financing as part of developing and advancing the company’s portfolio of programs. Prior to Kiniksa, Chris was at Synageva BioPharma Corp., where he held roles in global financial and operational leadership, most recently serving as Senior Vice President of Finance and Business Operations and Chief Accounting Officer. At Synageva, Chris also oversaw the company’s transition to the public markets and significant organizational growth. Earlier in his career, he held financial leadership positions at Panacos Pharmaceuticals Inc. and EPIX Pharmaceuticals Inc., both publicly traded biotechnology companies. He received an MBA from Boston University and a BA in economics from St. Lawrence University. He is also a Certified Public Accountant.
About KSQ Therapeutics
KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies. For more information, please visit the company’s website at www.ksqtx.com and follow @ksq_tx on Twitter.
© 2023 KSQ Therapeutics, Inc. All rights reserved.